Short latency afferent inhibition: A biomarker for mild cognitive impairment in Parkinson's disease?

Movement Disorders

Volumn 28, Issue 9, 2013, Pages 1285-1288

  Yarnall, Alison J ^a   Rochester, Lynn ^a   Baker, Mark R ^b   David, Rachel ^b   Khoo, Tien K ^a   Duncan, Gordan W ^a   Galna, Brook ^a   Burn, David J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Acetylcholine; Mild cognitive impairment; Neurophysiology; Parkinson's disease; Transcranial magnetic stimulation

Indexed keywords

BIOLOGICAL MARKER;

AGED; ARTICLE; CHOLINERGIC ACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; EVOKED MUSCLE RESPONSE; EXPLORATORY RESEARCH; FEMALE; HUMAN; INHIBITION KINETICS; LATENT PERIOD; MALE; MEDIAN NERVE; MILD COGNITIVE IMPAIRMENT; MOTOR CORTEX; PARKINSON DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; SENSORY NERVE; TRANSCRANIAL MAGNETIC STIMULATION;

ACETYLCHOLINE; MILD COGNITIVE IMPAIRMENT; NEUROPHYSIOLOGY; PARKINSON'S DISEASE; TRANSCRANIAL MAGNETIC STIMULATION;

AGED; CASE-CONTROL STUDIES; COGNITION DISORDERS; EVOKED POTENTIALS, MOTOR; FEMALE; HUMANS; INHIBITION (PSYCHOLOGY); MALE; MOTOR CORTEX; PARKINSON DISEASE; REACTION TIME; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 84883555417     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25360     Document Type: Article

References (26)

1. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 2005;58:773-776.
2. Compta Y, Parkkinen L, O'Sullivan SS, et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 2011;134:1493-1505.
3. Kempster PA, O'Sullivan SS, Holton JL, Revesz T, Lees AJ. Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain 2010;133:1755-1762.
4. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003;60:1745-1748.
5. Tiraboschi P, Hansen LA, Alford M, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000;54:407-411.
6. Meyer PM, Strecker K, Kendziorra K, et al. Reduced alpha 4 beta 2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry 2009;66:866-877.
7. Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012;27:349-356.
8. Di Lazzaro V, Oliviero A, Tonali PA, et al. Noninvasive in vivo assessment of cholinergic cortical circuits in AD using transcranial magnetic stimulation. Neurology 2002;59:392-397.
9. Nardone R, Bergmann J, Kronbichler M, et al. Abnormal short latency afferent inhibition in early Alzheimer's disease: a transcranial magnetic demonstration. J Neural Transm 2008;115:1557-1562.
10. Di Lazzaro V, Pilato F, Dileone M, et al. Functional evaluation of cerebral cortex in dementia with Lewy bodies. Neuroimage 2007;37:422-429.
11. Di Lazzaro V, Oliviero A, Profice P, et al. Muscarinic receptor blockade has differential effects on the excitability of intracortical circuits in the human motor cortex. Exp Brain Res 2000;135:455-461.
12. Celebi O, Temucin CM, Elibol B, Saka E. Short latency afferent inhibition in Parkinson's disease patients with dementia. Mov Disord 2012;27:1052-1055.
13. Tokimura H, Di Lazzaro V, Tokimura Y, et al. Short latency inhibition of human hand motor cortex by somatosensory input from the hand. J Physiol (Lond) 2000;523(pt 2):503-513.
14. Sakuma K, Murakami T, Nakashima K. Short latency afferent inhibition is not impaired in mild cognitive impairment. Clin Neurophysiol 2007;118:1460-1463.
15. Tsutsumi R, Hanajima R, Hamada M, et al. Reduced interhemispheric inhibition in mild cognitive impairment. Exp Brain Res 2012;218:21-26.
16. Francis PT. Biochemical and pathological correlates of cognitive and behavioural change in DLB/PDD. J Neurol 2009;256(suppl 3):280-285.
17. Di Lazzaro V, Pilato F, Dileone M, et al. Segregating two inhibitory circuits in human motor cortex at the level of GABAA receptor subtypes: a TMS study. Clin Neurophysiol 2007;118:2207-2214.
18. Di Lazzaro V, Pilato F, Dileone M, Tonali PA, Ziemann U. Dissociated effects of diazepam and lorazepam on short-latency afferent inhibition. J Physiol 2005;569:315-323.
19. Alle H, Heidegger T, Krivanekova L, Ziemann U. Interactions between short-interval intracortical inhibition and short-latency afferent inhibition in human motor cortex. J Physiol 2009;587:5163-5176.
20. Udupa K, Ni Z, Gunraj C, Chen R. Interactions between short latency afferent inhibition and long interval intracortical inhibition. Exp Brain Res 2009;199:177-183.
21. Kish SJ, Rajput A, Gilbert J, Rozdilskv B, Chang LJ, Shannak K, Hornykiewicz O. Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss. Ann Neurol 1986;20:26-31.
22. Emir UE, Tuite PJ, Oz G. Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 tesla proton MRS [serial online]. PLoS ONE 2012;7:e30918.
23. Halliday GM, Macdonald V, Henderson JM. A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease. Brain 2005;128:2272-2280.
24. Helmich RC, Baumer T, Siebner HR, Bloem BR, Munchau A. Hemispheric asymmetry and somatotopy of afferent inhibition in healthy humans. Exp Brain Res 2005;167:211-219.
25. Sailer A, Cunic DI, Paradiso GO, et al. Subthalamic nucleus stimulation modulates afferent inhibition in Parkinson disease. Neurology 2007;68:356-363.
26. Sailer A, Molnar GF, Paradiso G, Gunraj CA, Lang AE, Chen R. Short and long latency afferent inhibition in Parkinson's disease. Brain 2003;126:1883-1894.